ALKEM — Alkem Laboratories Share News
0.000.00%
Last trade - 00:00- IN₹603.80bn
- IN₹588.95bn
- IN₹147.12bn
Brief: Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients
Brief: Alkem Labs Launches Renocia Exo, Ginsenoside Exosome-Based Hair Growth Serum
Brief: Alkem Labs Board Approves Investment Of Up To 750 Million Rupees For New Block At Baddi Manufacturing Facility
Brief: Alkem Laboratories Q1 Consol Revenue From Operations 37.4 Billion Rupees
Brief: Alkem Labs Says US FDA Classified Inspection Status Of Amaliya Facility As Official Action Indicated
Brief: Alkem Labs Acquires Rights Shares Aggregating To 11 Billion Rupees Offered By Alkem Medtech
Brief: Alkem Labs Says Commissioner Of Income Tax Deletes Disallowances Involving Tax Amount Of 6.61 Billion Rupees
Indian pharma stocks up on report US taps drugmakers for critical cancer drug
Brief: Alkem Labs Launches Semaglutide In Single-Shot Pre-Filled Syringes At Price Starting 350 Rupees
Brief: Alkem Laboratories Q4 Consol Net Profit 2.36 Billion Rupees Ibes Profit Est. 4.7 Billion Rupees
Brief: Alkem Labs Says US FDA Conducts Unannounced Inspection At Alkem CRO Facility
India's Alkem Laboratories rises after GST demand relief order
Brief: Alkem Labs Says Order-In-Appeal Drops Tax Demand Of 696.6 Million Rupees
Brief: Alkem Labs Gets Tax Demand Of 3.3 Billion Rupees
India's Alkem Laboratories falls after CEO resigns
Brief: Alkem Labs Says Board Approves Increase Investment To Upto 10.36 Bln Rupees From 5.33 Bln Rupees For Ujjain Facility
Brief: Alkem Labs Incorporates Wholly Owned Subsidiary In Dubai Healthcare City, Uae
Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy
Analysts upbeat on semaglutide opportunity as patent expiry triggers India generics